Using a new treatment to fight lung infections caused by Pseudomonas aeruginosa in patients with bronchiectasis
Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
This study is testing a new inhalable treatment for people with bronchiectasis who have tough lung infections caused by Pseudomonas aeruginosa, aiming to help them breathe better and reduce infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vast Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project ID | NIH-11065101 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for bronchiectasis patients suffering from Pseudomonas aeruginosa infections, which are known to cause severe respiratory issues. The approach involves using a nitric oxide-releasing prodrug that can be inhaled, allowing for targeted delivery of this antibacterial agent directly to the lungs. By addressing the challenges of antibiotic resistance and biofilm formation, this treatment aims to improve patient outcomes and reduce the frequency of infections. The study will evaluate the effectiveness of this new therapy in preclinical models before moving to clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bronchiectasis who are experiencing recurrent infections caused by Pseudomonas aeruginosa.
Not a fit: Patients who do not have bronchiectasis or are not infected with Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with chronic lung infections, potentially reducing morbidity and mortality associated with bronchiectasis.
How similar studies have performed: Preliminary studies have shown promise in using nitric oxide for treating bacterial infections, indicating potential success for this novel approach.
Where this research is happening
Morrisville, UNITED STATES
- Vast Therapeutics, INC. — Morrisville, United States (Active)
Researchers
- Principal investigator: Stasko, Nathan Allan — Vast Therapeutics, INC.
- Study coordinator: Stasko, Nathan Allan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.